Skip to main content

Table 1 Demographic and clinical data of patients with and without foot and/or ankle arthritis

From: Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study

 

With FAA

Without FAA

P-values

(598, 29.2%)

(1448, 70.8%)

Demographic Characteristics

 Female, n (%)

520 (87.0)

1209 (83.5)

0.05

 Age at the time of enrollment, years

54.1 ± 12.6

54.4 ± 13.0

0.63

 Disease duration, years

8.5 ± 8.3

7.4 ± 7.0

< 0.01

  Disease duration < 1 year, n (%)

99 (16.6)

228 (15.8)

0.69

  Disease duration < 2 years, n (%)

170 (28.5)

399 (27.7)

0.70

  Disease duration < 3 years, n (%)

200 (33.6)

509 (35.3)

0.47

  Disease duration < 4 years, n (%)

241 (40.4)

622 (43.1)

0.28

  Disease duration < 5 years, n (%)

273 (45.8)

71 (49.6)

 

  Disease duration ≥5 years, n (%)

323 (54.2)

727 (50.4)

0.12

 Body mass index, kg/m2

22.6 ± 3.6

22.6 ± 3.2

0.97

 Current/ex-smoker, n (%)

89 (14.9)

217 (15.0)

1.00

 Presence of RA-associated lung diseases, n (%)

21 (3.5)

47 (3.3)

0.79

 Positive for rheumatoid factor, n (%)

491 (85.1)

1174 (83.5)

0.38

 Positive for anti-cyclic citrullinated peptide, n (%)

404 (84.7)

1046 (85.1)

0.88

Radiographic damage

 Hand X-ray

   

  Erosion, n (%)

197 (40.0)

417 (34.8)

< 0.05

  Joint space narrowing, n (%)

226 (45.8)

555 (46.5)

0.83

 Feet X-ray

  Erosion, n (%)

153 (36.7)

247 (29.1)

< 0.01

  Joint space narrowing, n (%)

107 (25.7)

224 (26.5)

0.79

Medication

 Current glucocorticoid use, n (%)

497 (83.1)

1169 (80.7)

0.21

 Daily dose (prednisolone equivalent), mg

5.2 ± 10.7

4.3 ± 4.2

< 0.01

 Current use of MTX, n (%)

567 (94.8)

1337 (92.3)

0.05

 Previous use of bDMARDs, n (%)

145 (24.2)

233 (16.1)

< 0.01

Disease activity

 Swollen joint count (44 joints examined)

8.9 ± 6.8

3.9 ± 4.4

< 0.01

 Tender joint count (44 joints examined)

11.9 ± 8.6

4.9 ± 5.0

< 0.01

 Patients Global Assessment score (1–10 mm)

6.7 ± 2.3

5.7 ± 2.6

< 0.01

 Evaluator’s Global Assessment score (1–10 mm)

6.0 ± 5.2

5.2 ± 2.6

< 0.01

 ESR, mm/h

48.8 ± 29.2

41.3 ± 27.2

< 0.01

 CRP, mg/dL

2.6 ± 3.3

1.7 ± 2.3

< 0.01

 DAS28-ESR score

5.6 ± 1.4

4.7 ± 1.5

< 0.01

 DAS28-CRP score

4.9 ± 1.4

4.0 ± 1.5

< 0.01

 SDAI score

30.3 ± 14.3

21.3 ± 12.8

< 0.01

 CDAI score

27.8 ± 13.2

19.7 ± 11.9

< 0.01

 RAPID3 score

15.9 ± 6.0

12.4 ± 6.6

< 0.01

The proportion of patients with remission

 DAS28-ESR, n (%)

21 (3.5)

153 (10.7)

< 0.01

 DAS28-CRP, n (%)

38 (6.4)

305 (21.4)

< 0.01

 SDAI, n (%)

8 (1.3)

112 (7.7)

< 0.01

 CDAI, n (%)

3 (0.5)

69 (4.8)

< 0.01

 RAPID3, n (%)

12 (2.0)

128 (8.9)

< 0.01

 Boolean-based criteria, n (%)

5 (0.8)

82 (5.8)

< 0.01